Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.

Schoels MM, van der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Nishimoto N, Smolen JS.

Ann Rheum Dis. 2013 Apr;72(4):583-9. doi: 10.1136/annrheumdis-2012-202470. Epub 2012 Nov 10. Review. Erratum in: Ann Rheum Dis. 2013 Jun;72(6):1110. Murikama, Miho M [corrected to Murakami, Miho].

2.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

3.

IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2012;70(3):195-9. Review.

4.

Tocilizumab for treating juvenile idiopathic arthritis.

Turnier JL, Brunner HI.

Expert Opin Biol Ther. 2016;16(4):559-66. doi: 10.1517/14712598.2016.1150997. Epub 2016 Feb 27. Review.

PMID:
26848760
5.

Antagonizing IL-6 in ankylosing spondylitis: a short review.

Rajalingham S, Das S.

Inflamm Allergy Drug Targets. 2012 Aug 1;11(4):262-5. Review.

PMID:
22452603
6.

Targeting interleukin-6 in rheumatoid arthritis.

Md Yusof MY, Emery P.

Drugs. 2013 Mar;73(4):341-56. doi: 10.1007/s40265-013-0018-2. Review.

PMID:
23456676
7.

Clinical value of blocking IL-6 receptor.

Mima T, Nishimoto N.

Curr Opin Rheumatol. 2009 May;21(3):224-30. doi: 10.1097/BOR.0b013e3283295fec. Review.

PMID:
19365268
8.

Interleukin 6 inhibition - RA and beyond.

Woodrick RS, Ruderman EM.

Bull NYU Hosp Jt Dis. 2011;69(3):225-9. Review.

9.

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

Herlin T.

Expert Rev Clin Immunol. 2012 Aug;8(6):517-25. Review.

PMID:
22992145
10.

Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).

Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2016 Nov 17;11:CD012437. Review.

PMID:
27855242
11.

Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis.

June RR, Olsen NJ.

Expert Opin Biol Ther. 2016 Oct;16(10):1303-9. doi: 10.1080/14712598.2016.1217988. Epub 2016 Aug 8. Review.

12.

Targeting interleukin-6 in pediatric rheumatic diseases.

De Benedetti F.

Curr Opin Rheumatol. 2009 Sep;21(5):533-7. doi: 10.1097/BOR.0b013e32832f1445. Review.

PMID:
19593141
13.

The role of tocilizumab in the management of rheumatoid arthritis.

Ash Z, Emery P.

Expert Opin Biol Ther. 2012 Sep;12(9):1277-89. doi: 10.1517/14712598.2012.707178. Epub 2012 Jul 31. Review.

PMID:
22849354
14.

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, Buch MH.

Ann Rheum Dis. 2010 Jun;69(6):976-86. doi: 10.1136/ard.2009.126573. Epub 2010 May 6. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20447957
15.

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.

Schoels M, Aletaha D, Smolen JS, Wong JB.

Ann Rheum Dis. 2012 Aug;71(8):1303-8. doi: 10.1136/annrheumdis-2011-200490. Epub 2012 Jan 30. Review.

PMID:
22294630
16.

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME.

Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii2-22. Review. No abstract available. Erratum in: Ann Rheum Dis. 2008 Feb;67(2):280.

17.

Interleukin-6 in rheumatoid arthritis.

Nishimoto N.

Curr Opin Rheumatol. 2006 May;18(3):277-81. Review.

PMID:
16582692
18.

Tocilizumab in pediatric rheumatology: the clinical experience.

Gurion R, Singer NG.

Curr Rheumatol Rep. 2013 Jul;15(7):338. doi: 10.1007/s11926-013-0338-y. Review.

PMID:
23715975
19.

Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.

Song SN, Yoshizaki K.

Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):307-16. doi: 10.1517/17425255.2015.992779. Epub 2014 Dec 10. Review.

PMID:
25491492
20.

Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.

Mircic M, Kavanaugh A.

Exp Cell Res. 2011 May 15;317(9):1286-92. doi: 10.1016/j.yexcr.2011.02.017. Epub 2011 Mar 22. Review.

PMID:
21439276

Supplemental Content

Support Center